

CELLECTIS

French limited liability company (*société anonyme*)
with share capital of € 5,014,561.35
Registered Office: 8, rue de la Croix Jarry - 75013 Paris
Paris trade and companies register No. 428 859 052
(the "Company")

Information regarding the director nominee

SHAREHOLDERS MEETING OF JUNE 26, 2025

1. **NAME AND FIRST NAME:** BERGSTROM, Donald
2. **DATE AND PLACE OF BIRTH:** October 29, 1971, Boston, Massachusetts (USA)
3. **AGE :** 53
4. **NATIONALITY :** American
5. **PROFESSIONAL PROFILE AND PROFESSIONAL ACTIVITIES DURING THE PAST FIVE YEARS**

Dr. Bergstrom currently serves as President, Research & Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company.

Prior to his tenure at Relay Therapeutics, Dr. Bergstrom was Chief Medical Officer at Mersana Therapeutics, where he led the advancement of two products based on Mersana's proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials. Prior to Mersana, he was Global Head of Translational and Experimental Medicine at Sanofi Oncology.

Dr. Bergstrom holds an M.D. from the University of Washington, Seattle, and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed his post-doctoral training. He was a resident in clinical pathology at the University of Washington.

On-going mandates:
none

Other mandates and functions held during the past five years:

 - Fusion Pharmaceuticals, director (2021-2024)
6. **CURRENT POSITION IN THE COMPANY**
director
7. **COMPANY SHARES OWNED BY THE DIRECTOR NOMINEE**
none